
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
Vascepa is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients.
Medication Pearl of the Day: Vascepa (icosapent ethyl)
Indication: Vascepa is an ethyl ester of (EPA) indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular (CV) disease or diabetes mellitus and 2 or more additional risk factors for CV disease.
Insight:
Sources:





